Compare Gap Inc (GAP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Gap Inc trades at $20.9 (market cap $7.74B), while State Street SPDR S&P Biotech ETF trades at $157.76. The key difference: Gap Inc pays a 3.25% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Gap Inc nearer its low. Which is the better fit depends on your goals.
| GAP | XBI | |
|---|---|---|
Market Cap | $7.74B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $29.13 | $164.28 |
52-Week Low | $18.35 | $85.16 |
Enterprise Value | $10.82B | — |
Dividend Yield | 3.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap trades at $20.47, down 0.24% on the day, with a bullish technical signal supported by strong momentum indicators. The stock shows attractive valuation metrics, including a P/E of 8.12 and P/S of 0.51, while recent earnings have generally beaten expectations. Operating cash flow remains robust at $1.49 billion for 2025, and the company continues its digital transformation with AI initiatives.
The outlook is positive with a consensus price target of $26.64, implying 30% upside. Risks include competitive pressures and ongoing investigations by Pomerantz Law Firm. Analyst sentiment is mixed but leans bullish, with 39.58% recommending buy. The stock presents a value opportunity if turnaround efforts sustain momentum.
XBI, the SPDR S&P Biotech ETF, trades at $157.37, up 1.88% today, with a bullish technical signal from moving averages and strong momentum indicators. The ETF has surged nearly 17% in a month, driven by positive clinical trial news and increased M&A activity in the biotech sector. Analyst coverage is limited to one hold rating, reflecting cautious optimism amid high volatility.
Outlook remains positive due to sector tailwinds like AI-driven drug discovery and robust M&A, but risks include policy uncertainty and the fund's high beta. Investors should weigh the potential for continued growth against inherent volatility in small- and mid-cap biotech holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
